Table 2. Standardized Incidence Ratios (SIRs) for Cutaneous Cancers.
| Cancer type | No. of cases (%) | SIR (95% CI) | P valuea |
|---|---|---|---|
| All skin cancer types, excluding keratinocyte carcinomas | 2380 (100) | 2.18 (2.09-2.27) | <.001 |
| Melanoma | 1471 (61.8) | 1.52 (1.44-1.60) | <.001 |
| Superficial spreading melanoma | 428 (18.0) | 1.30 (1.18-1.42) | <.001 |
| Lentigo maligna melanoma | 114 (4.8) | 1.31 (1.08-1.58) | .006 |
| Nodular melanoma | 105 (4.4) | 1.60 (1.31-1.94) | <.001 |
| Acral lentiginous melanoma | 13 (0.5) | 1.32 (0.70-2.26) | .39 |
| Desmoplastic melanoma | 18 (0.8) | 1.56 (0.92-2.46) | .10 |
| Amelanotic melanoma | 12 (0.5) | 3.14 (1.62-5.49) | .001 |
| Other melanoma subtypes or not specified | 781 (32.8) | 1.69 (1.57-1.81) | <.001 |
| Merkel cell carcinoma | 334 (14.0) | 16.2 (14.5-18.1) | <.001 |
| Adnexal cancersb | 254 (10.7) | 10.1 (8.88-11.4) | <.001 |
| Sebaceous carcinoma | 170 (7.1) | 15.2 (13.0-17.7) | <.001 |
| Eccrine carcinoma | 51 (2.1) | 5.59 (4.16-7.35) | <.001 |
| Sweat gland adenocarcinoma | 8 (0.3) | 8.04 (3.47-15.8) | <.001 |
| Nodular hidradenoma, malignant | 7 (0.3) | 6.48 (2.60-13.3) | <.001 |
| Sclerosing sweat duct carcinoma | 10 (0.4) | 4.93 (2.36-9.06) | <.001 |
| Eccrine | |||
| Papillary adenocarcinoma | 1 (0.04) | 2.42 (0.06-13.5) | .68 |
| Poroma, malignant | 11 (0.5) | 6.51 (3.25-11.6) | <.001 |
| Adenocarcinoma | 8 (0.3) | 5.66 (2.44-11.1) | <.001 |
| Mucinous adenocarcinoma | 6 (0.3) | 3.99 (1.47-8.69) | .009 |
| Apocrine adenocarcinoma | 6 (0.3) | 7.56 (2.78-16.5) | <.001 |
| Adenoid cystic carcinoma | 3 (0.1) | 3.73 (0.77-10.9) | .10 |
| Skin appendage carcinoma | 24 (1.0) | 7.25 (4.65-10.8) | <.001 |
| Sarcomasc | 27 (1.1) | 1.43 (0.94-2.08) | .09 |
| Dermatofibrosarcoma protuberans | 11 (0.5) | 0.82 (0.41-1.46) | .62 |
| Cutaneous | |||
| Leiomyosarcoma | 8 (0.3) | 2.32 (1.00-4.56) | .05 |
| Angiosarcoma | 7 (0.3) | 3.62 (1.46-7.46) | .008 |
| Glomangiosarcoma | 1 (0.04) | 56.2 (1.42-313) | .04 |
| Kaposi sarcoma | 186 (7.8) | 20.5 (17.7-23.7) | <.001 |
| Lymphomad | 108 (4.5) | 2.25 (1.84-2.71) | <.001 |
| T-cell lymphoma | 85 (3.6) | 1.95 (1.56-2.41) | <.001 |
| Mycosis fungoides | 29 (1.2) | 1.05 (0.71-1.51) | .83 |
| Sézary syndrome | 2 (0.1) | 2.25 (0.27-8.13) | .45 |
| Anaplastic large cell lymphoma | 28 (1.2) | 6.82 (4.53-9.85) | <.001 |
| Subcutaneous panniculitis-like T-cell lymphoma | 2 (0.1) | 13.2 (1.59-47.5) | .02 |
| Extranodal natural killer/T-cell lymphoma, nasal type | 2 (0.1) | 44.3 (5.37-160) | .002 |
| Peripheral T-cell lymphoma, not otherwise specified | 22 (0.9) | 2.01 (1.26-3.05) | .004 |
| Diffuse large B-cell lymphoma | 23 (1.0) | 5.17 (3.28-7.76) | <.001 |
a
The SIR estimates were considered significant at P < .002 based on a Bonferroni correction for multiple comparisons of 25 cancer types.
b
There were no cases of the following cutaneous adnexal cancers: malignant eccrine spiradenoma, ceruminous adenocarcinoma, trichilemmocarcinoma, malignant pilar tumor, and pilomatrix carcinoma.
c
There were no cases of the following cutaneous sarcomas: clear cell sarcoma, malignant peripheral nerve sheath tumor, liposarcoma, and angiomyoliposarcoma.
d
There were no cases of the following cutaneous lymphomas or histiocytic disorders: adult T-cell leukemia-lymphoma, follicle center lymphoma, and Langerhans cell histiocytosis.